Talphera (R5XA) AI Stock Analysis

Company Guidance

Management reiterated that the NEPHRO CRRT registrational study is ~75% enrolled with all sites activated and remains on track to complete enrollment later this year, with top‑line data expected ~4–5 weeks after completion and a PMA submission targeted in the first half of 2027 (with potential PMA approval expected in 2027); two conditional financing tranches totaling approximately $16.0M are expected to close around the top‑line/readout and, together with $17.1M cash at June 30, 2026, are believed to fund the company through a potential 2027 approval. Commercial and market metrics highlighted include an updated U.S. CRRT procedure estimate of ~200,000 in 2027 (a 21% increase from a prior 165,000 estimate), ~70 institutions representing >50% of procedures, citrate use in ~25% of U.S. sites (i.e., ~75% without citrate), nafamostat use ~80% in Japan (2018) and approved in South Korea since 2005, and primary market research with >30 physicians; operational/treatment metrics discussed include 80–85% of patients at therapeutic range on the starting dose (near 100% within ~30 minutes), typical nafamostat dosing around 20–25 mg/hr versus a 50 mg/hr ceiling with most patients titrated below half the maximum, titration opportunities every 15 minutes, and Q2 2026 cash operating expenses of $3.9M ($3.7M excluding stock‑based comp) versus $3.7M ($3.5M ex‑comp) in Q2 2025.